The original success of the copyright undeniably reshaped the drug landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. While early returns were significant, the cessation of patents and the rise of discounted alternatives have eroded the customer base. Thus, a thorough evaluation of ongoing revenue